Combinostics

Company profile

About Combinostics

Combinostics is a medical imaging AI company specializing in neurological disorders, offering the only complete AI solution for entire patient care pathways of major neurodegenerative diseases. Founded by experts with over 20 years of neuroimaging experience, the company developed the cNeuro platform, which integrates multiple applications to support clinicians from early detection through disease management. The cNeuro platform consists of cMRI for fully automated brain MRI quantification, cDSI for AI-supported differential diagnosis and disease progression prediction, cPET for amyloid and FDG brain PET quantification, and cDAT for automated quantification of DAT SPECT images. The platform combines imaging biomarkers with clinical data, neuropsychological tests, and demographic information to provide comprehensive patient insights. Combinostics serves radiologists, neurologists, and memory clinics across health systems, enabling better collaboration between disciplines. The company's solutions support diagnosis of Alzheimer's disease, frontotemporal dementia, vascular dementia, dementia with Lewy bodies, and multiple sclerosis. With validated imaging biomarkers and machine learning methods trained on data from over 2,000 patients with confirmed neurodegenerative diseases, cNeuro provides quantitative, objective information that helps clinicians make earlier, more confident diagnoses and data-driven decisions about additional testing. The company maintains strong partnerships with leading Nordic institutions and the international clinical community.

Company description · Combinostics official website